Peregrine Capital Management LLC bought a new position in shares of Lexington Realty Trust in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 638,120 shares of the real estate investment trust's stock, valued at approximately $5,296,000.
Comment?

... And four years ago, the world's largest biotech devoted to antibiotics, Lexington drug giant Cubist Pharmaceuticals was acquired by Merck, which has a limited antibiotic pipeline. Cubist had demonstrated the potential of antibiotic development, with ...
Comment?

... tedizolid phosphate, Merck's ( MRK ) Sivextro. Sivextro was a big story back in 2013 and 2014 when Cubist Pharmaceuticals first acquired Trius, which developed tedizolid through Phase III, followed by Merck's acquisition of Cubist in 2014. ...
Comment?

... of Directors at ProQR Therapeutics and Verastem, Inc., and was previously a director on the boards of Cubist Pharmaceuticals, CoLucid Pharmaceuticals, and Magenta Therapeutics. Mr. Brumm joined Kaleido as its CFO in April 2018 and will continue to ...
Comment?

... n 2014, the company made three significant acquisitions: Schering-Plough, Idenix Pharmaceuticals, and Cubist Pharmaceuticals. At the time of this article's writing, the author did not have positions in any of the companies mentioned.
Comment?

A lab at the erstwhile Cubist Pharmaceuticals in 2010. As recent developments involving another drug manufacturer show, maintaining a steady flow of new drugs in development is vital because the bacteria that cause infectious diseases evolve to become less susceptible to treatments.
Comment?

... itself and senior management responsible for Merck's acquisition of another pharmaceutical firm, Cubist Pharmaceuticals, Inc. Feuer asserted the acquisition was ill-advised and reckless. He alleged Merck proceeded with the transaction although it ...
Comment?

... and Alliance Management at Juniper Pharmaceuticals. Previously, Joyce held leadership positions at Cubist Pharmaceuticals, where she was Senior Director, Program and Portfolio Management and at Genzyme, a Sanofi Company, where she was Senior ...
Comment?

... reports of difficulties obtaining Firazyr, which treats hereditary angioedema, a genetic disorder. Cubist Pharmaceuticals and Aegerion were also included on the list. "Shire is committed to developing therapies for rare diseases and specialized ...
Comment?

... in the coming years." Prior to joining Trevena, Ms. Bourdow was vice president of marketing at Cubist Pharmaceuticals, Inc., until its acquisition by Merck & Co., Inc. in January 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, ...
Comment?

Mr. Perez is the first independent member of the ImmusanT Board, which includes representatives from investors ARCH Venture Partners and Vatera Holdings LLC. A longtime executive and advisor in the biopharmaceutical industry, Mr. Perez served as the Chief Executive Officer of Cubist Pharmaceuticals, Inc. at the time the company was acquired by Merck in 2015. Prior to his tenure as CEO, Mr. Perez held multiple roles at Cubist, including President, Chief Operating Officer and Senior Vice President of Sales and Marketing, where he oversaw the launch of CubicinA .
Comment?

... a lipopeptide antibiotic is an FDA approved treatment for MRSA bacteria. The drug is manufactured by Cubist Pharmaceuticals, Inc. under brand name CUBICIN. As majority of the treatment involves prescription of generic drugs, the market is mainly ...
Comment?

... joining Tetraphase, Mr. Edwards served as senior director of marketing, Gram Negative Franchise, with Cubist Pharmaceuticals, Inc. (later acquired by Merck), where he was responsible for all pre-launch or post-launch marketing activities for ...
Comment?